Replimune Group Inc (REPL) Stock Price, Quote & News

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology

Sector: Healthcare

Phone: (781) 222-9600

Website: www.replimune.com

Address:

500 Unicorn Park Drive, Suite 303, Woburn, United States

buwl Jul. 23 at 2:45 AM

$REPL LOTS OF ROOM TO GAP UP NOW.

0 · Reply

Deekay1 Jul. 23 at 2:36 AM

$REPL surprised that 1 star loser anal lyst HC Wainwright hasn't popped up with his $0 price target..

0 · Reply

BNBComedian Jul. 23 at 2:29 AM

$REPL junk science

1 · Reply

buwl Jul. 23 at 1:58 AM

$REPL BUYOUT OFFER

1 · Reply

buwl Jul. 23 at 1:57 AM

$REPL

0 · Reply

YoloAlfred Jul. 23 at 1:46 AM

$REPL 🤔🤔🤔🤔

0 · Reply

Duke2021 Jul. 23 at 1:41 AM

$REPL Anyone have the overnight price on this?

1 · Reply

Golferhack12 Jul. 23 at 1:40 AM

$REPL is this gapping up pre-market anybody got a quote?

0 · Reply

RiskEprofit Jul. 23 at 1:09 AM

$REPL fuckkkkk

2 · Reply

justiceforb_85 Jul. 23 at 1:07 AM

$IOBT down today perhaps on $REPL news. Still hopeful on P3 data.

0 · Reply

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 11:03 AM EDT - 11 hours ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 11, 2025, 4:01 PM EDT - 11 days ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2025, 10:00 AM EDT - 7 weeks ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2025, 8:00 AM EDT - 7 weeks ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 22, 2025, 11:19 AM EDT - 2 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 7:00 AM EDT - 2 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:00 AM EDT - 2 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 9, 2025, 4:01 PM EDT - 2 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 5:00 AM EDT - 2 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Apr 28, 2025, 3:26 PM EDT - 3 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Feb 12, 2025, 4:21 PM EST - 5 months ago

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 8:00 AM EST - 5 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Dec 23, 2024, 8:00 AM EST - 7 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 29, 2024, 4:12 AM EST - 8 months ago

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 25, 2024, 11:55 PM EST - 8 months ago

Replimune Announces Pricing of Upsized Public Offering

Nov 25, 2024, 7:09 AM EST - 8 months ago

Replimune Announces Proposed Public Offering

Nov 21, 2024, 4:05 PM EST - 8 months ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Nov 9, 2024, 1:00 PM EST - 9 months ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Oct 30, 2024, 9:15 AM EDT - 9 months ago

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sep 15, 2024, 9:45 AM EDT - 11 months ago

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 1:01 PM EDT - 11 months ago

Replimune: Strong Data In A Highly Differentiated Space

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Jul 30, 2024, 4:01 PM EDT - 1 year ago

Replimune to Present at Two Upcoming Investor Conferences

Jun 7, 2024, 8:00 AM EDT - 1 year ago

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2024, 8:00 AM EDT - 1 year ago

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

Apr 7, 2024, 5:00 PM EDT - 1 year ago

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Mar 26, 2024, 7:30 AM EDT - 1 year ago

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Feb 8, 2024, 8:00 AM EST - 1 year ago

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Dec 28, 2023, 8:00 AM EST - 1 year ago

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 8:28 AM EST - 1 year ago

Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

Dec 5, 2023, 7:00 AM EST - 1 year ago

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Nov 8, 2023, 9:10 AM EST - 1 year ago

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Nov 7, 2023, 8:00 AM EST - 1 year ago

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Nov 3, 2023, 7:30 PM EDT - 1 year ago

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap

Oct 17, 2023, 3:00 AM EDT - 1 year ago

Tessellate BIO Emerges from Stealth

NAMS

Aug 14, 2023, 5:28 PM EDT - 2 years ago

Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Replimune Announces Sander Slootweg will Depart from its Board of Directors

Jul 9, 2023, 1:22 AM EDT - 2 years ago

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment

Jun 6, 2023, 10:00 AM EDT - 2 years ago

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

Jun 3, 2023, 2:15 PM EDT - 2 years ago

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2023, 4:01 PM EDT - 2 years ago

Replimune to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

buwl Jul. 23 at 2:45 AM

$REPL LOTS OF ROOM TO GAP UP NOW.

0 · Reply

Deekay1 Jul. 23 at 2:36 AM

$REPL surprised that 1 star loser anal lyst HC Wainwright hasn't popped up with his $0 price target..

0 · Reply

BNBComedian Jul. 23 at 2:29 AM

$REPL junk science

1 · Reply

buwl Jul. 23 at 1:58 AM

$REPL BUYOUT OFFER

1 · Reply

buwl Jul. 23 at 1:57 AM

$REPL

0 · Reply

YoloAlfred Jul. 23 at 1:46 AM

$REPL 🤔🤔🤔🤔

0 · Reply

Duke2021 Jul. 23 at 1:41 AM

$REPL Anyone have the overnight price on this?

1 · Reply

Golferhack12 Jul. 23 at 1:40 AM

$REPL is this gapping up pre-market anybody got a quote?

0 · Reply

RiskEprofit Jul. 23 at 1:09 AM

$REPL fuckkkkk

2 · Reply

justiceforb_85 Jul. 23 at 1:07 AM

$IOBT down today perhaps on $REPL news. Still hopeful on P3 data.

0 · Reply

ProKnifeCatcher87 Jul. 23 at 1:06 AM

$REPL trading at 50% cash wud up wit the $17 pt issued after today’s news ?!?! i’m in 13,000 shares now under $3 🤷🏻‍♂️🤷🏻‍♂️🤷🏻‍♂️🤷🏻‍♂️🤷🏻‍♂️😧😧😧🤡🤡

1 · Reply

SauceMan912 Jul. 23 at 1:00 AM

$REPL

5 · Reply

Jackie_O_ Jul. 23 at 12:45 AM

$REPL Many drugs or treatments that initially receive a CRL get approved eventually. Once the dust settles, this will likely trade around 5-6 until a positive catalyst. Bio is a tough business and the new FDA appears to be making it tougher (although they claim the opposite). Good luck everyone 🍀🌟

2 · Reply

YearOfTheRabbit Jul. 23 at 12:35 AM

$REPL ok top loser, I bought the dip and traded 3 times holding last purchase. Could go back to $7 quick

0 · Reply

Yamkatel03 Jul. 23 at 12:35 AM

$REPL we should be like this

0 · Reply

Biotoneten Jul. 23 at 12:10 AM

$REPL Made $1700 here between two trades. Should have been more, but it started sucking wind mid day.

0 · Reply

Heroforest Jul. 23 at 12:09 AM

$REPL there is also a rule of thumb that FDA never approves a drug at the very last day, the closer to the PUDFA date the more likely a CRL….after you get into the last 10 days count.

1 · Reply

Rasto2020 Jul. 23 at 12:04 AM

$REPL I’ll be watching.,, interesting

1 · Reply

ArtemisHF Jul. 23 at 12:03 AM

$REPL what a waste of time and money today was. A total fuckup of non-movement

0 · Reply

CYB3RFR34K Jul. 23 at 12:02 AM

$REPL why do i see this???

3 · Reply

omega42 Jul. 22 at 11:59 PM

$REPL in Q1 they had 480M in cash which is about 2.5 years based on 50M a Q cash burn. Another trial will be costly and will take time which means about 3-4 year set back

0 · Reply

BiotechBonesaw Jul. 22 at 11:54 PM

$REPL fake news

0 · Reply

Market Cap	950.10M
Revenue (ttm)	0.00
Net Income (ttm)	-247.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	86,810,703
Avg Vol	3,376,434
Day's Range	N/A - N/A
Shares Out	77.09M
Stochastic %K	1%
Beta	0.61
Analysts	Strong Sell
Price Target	$22.25